Lymphomas
51
6
6
29
Key Insights
Highlights
Success Rate
85% trial completion
Published Results
11 trials with published results (22%)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
9.8%
5 terminated out of 51 trials
85.3%
-1.2% vs benchmark
0%
0 trials in Phase 3/4
38%
11 of 29 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 29 completed trials
Clinical Trials (51)
A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas
Specimen Collections From Participants With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cancer
Collection of Tissue Samples for Cancer Research
Trial of the Combination of Bortezomib and Clofarabine in Adults With Relapsed Solid Tumors
Study of FF-10502-01 in Patients With Advanced Solid Tumors and Lymphomas
Interest of Individual Biomarkers From the Identification of Tumor Genotype by High-throughput Molecular Techniques
Selinexor, High-dose Methotrexate, and Rituximab Combined With Radiotherapy for Newly Diagnosed, Transplant-ineligible Patients With Central Nervous System Lymphoma: An Open-label, Single-arm, Multicenter Phase II Study
Safety and Clinical Activity of KT-253 in Adult Patients with High Grade Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphoma, Solid Tumors
Safety and Pharmacokinetic Study of RRx-001 in Cancer Subjects
CAR-T Technology for Recurrent/Refractory Malignant Hematological and Lymphatic Tumors
TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas
Epoetin Alfa Biosimilar in the Management of Chemotherapy-Induced Symptomatic Anemia in Haematology and Oncology
A Study of the Clinical Application of [18F]RCCB6 and [68Ga]Ga-NOTA-RCCB6 PET/CT Imaging in the Diagnosis of CD70-expressing Multiple Tumors
A Study of HMPL-689 in Patients With Lymphomas Failed of Standard of Care or no Standard of Care Existed
A Double-Blind Study in Healthy Volunteers to Assess the Effect of E7080 on the QTc Interval
T-cell Depleted Alternative Donor Transplantation
Nonmyeloablative Haploidentical Transplant Followed by MLN9708
Expanded Access Protocol (EAP) Using the CliniMACS® Device for Pediatric Haplocompatible Donor Stem Cell Transplant
Phase I/Ib Study of GWN323 Alone and in Combination With PDR001 in Patients With Advanced Malignancies and Lymphomas
A Trial of LEE011 in Patients With Advanced Solid Tumors or Lymphoma.